A federal judge in Massachusetts has sanctioned Manhattan plaintiffs firm Milberg for orchestrating an “elaborate scheme of deceptive conduct,” and dismissed a plaintiff’s qui tam action.

U.S. District Judge F. Dennis Saylor IV found that, at Milberg’s behest, a physician and medical researcher conducted a fraudulent “medical research” survey of doctors concerning their prescription of the drug Namenda to Medicare patients.